Cancer immunotherapies - Aduro BioTech

Drug Profile

Cancer immunotherapies - Aduro BioTech

Alternative Names: CG-1940/CG-8711; CG-8123; GVAX Leukemia; GVAX Pancreas; GVAX Prostate; STINGVAX™

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Cell Genesys
  • Developer Aduro BioTech; ANI Pharmaceuticals; BioSante Pharmaceuticals; Cell Genesys; Dana-Farber Cancer Institute; Hussman Foundation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Cancer vaccines; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I/II Prostate cancer
  • Phase I Colorectal cancer
  • No development reported Breast cancer; Cancer; Chronic myeloid leukaemia; Malignant melanoma; Multiple myeloma
  • Discontinued Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 28 Dec 2016 Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03006302)
  • 12 Dec 2016 Phase-I development is ongoing in Colorectal-cancer in USA (Intradermal, Injection)
  • 01 Dec 2016 Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Colorectal cancer (Second-line therapy, Combination therapy, Metastatic disease, Late stage disease) in USA (NCT02981524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top